A detailed history of Qube Research & Technologies LTD transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 160,172 shares of SUPN stock, worth $5.15 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
160,172
Previous 9,603 1567.94%
Holding current value
$5.15 Million
Previous $327,000 1210.09%
% of portfolio
0.01%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.99 - $33.85 $3.91 Million - $5.1 Million
150,569 Added 1567.94%
160,172 $4.28 Million
Q1 2024

May 14, 2024

SELL
$27.11 - $35.17 $2.3 Million - $2.98 Million
-84,722 Reduced 89.82%
9,603 $327,000
Q4 2023

Feb 13, 2024

BUY
$22.72 - $29.68 $2.14 Million - $2.8 Million
94,325 New
94,325 $2.73 Million
Q2 2023

Aug 14, 2023

BUY
$29.91 - $38.73 $388,590 - $503,180
12,992 Added 28.04%
59,318 $1.78 Million
Q1 2023

May 15, 2023

BUY
$34.93 - $42.03 $494,294 - $594,766
14,151 Added 43.98%
46,326 $1.68 Million
Q4 2022

Feb 14, 2023

BUY
$31.09 - $37.88 $522,498 - $636,611
16,806 Added 109.35%
32,175 $1.15 Million
Q3 2022

Nov 14, 2022

BUY
$28.79 - $35.41 $442,473 - $544,216
15,369 New
15,369 $520,000
Q1 2022

May 09, 2022

SELL
$28.51 - $32.9 $1.48 Million - $1.7 Million
-51,750 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$26.37 - $34.22 $1.36 Million - $1.77 Million
51,750 New
51,750 $1.51 Million
Q3 2020

Nov 12, 2020

SELL
$20.2 - $25.05 $211,574 - $262,373
-10,474 Closed
0 $0
Q2 2020

Aug 14, 2020

SELL
$17.09 - $24.89 $3,845 - $5,600
-225 Reduced 2.1%
10,474 $249,000
Q1 2020

May 15, 2020

SELL
$14.45 - $24.69 $354,935 - $606,460
-24,563 Reduced 69.66%
10,699 $192,000
Q4 2019

Feb 13, 2020

BUY
$19.93 - $29.13 $702,771 - $1.03 Million
35,262 New
35,262 $836,000

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.72B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.